First Diagnostic Test to Detect Risk of Preterm Birth

Sera Prognostics is a leading women's health company utilizing a proprietary proteomics and bioinformatics platform to discover, develop, and commercialize biomarker tests for major pregnancy-related conditions.

Sera's first commercial product, the PreTRM® Test, is the only broadly validated, commercially available blood-based biomarker test to predict the risk of preterm birth. Results from clinical studies show positive effects on the babies’ health, shorter Neonatal Intensive Care Unit stays, and reduced cost.

Sera is also developing a pipeline of novel blood-based biomarker tests for a number of additional pregnancy conditions with the aim of improving maternal and neonatal health and lower healthcare costs.

Investing partner / fund: